HopeStage
Back to all studies
CompletedNCT00071747

Lamotrigine added to antipsychotic treatment for schizophrenia

About this titleRead the official source — NCT00071747

This study evaluated the effectiveness of lamotrigine for people with schizophrenia.

Medication studyAges 18–65United States
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the effectiveness of lamotrigine for people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Little Rock and 31 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateAugust 2003
Recruitment status
Completed
Enrollment listed in the registry
176
Sponsor
GlaxoSmithKline
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00071747
Official title
Show the full official title

A Multi-Center, Double Blind, Placebo-controlled, Randomized, Parallel Group Evaluation of the Efficacy of a Flexible Dose of Lamotrigine Versus Placebo As Add-On Therapy In Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Little Rock · Garden Grove · La Mesa

28 more locations
  • National City
  • Oceanside
  • Rosemead
  • San Diego
  • Hartford
  • Maitland
  • North Miami
  • Granite City
  • Glen Burnie
  • Rockville
  • Boston
  • Reno
  • Clementon
  • Kenilworth
  • Orangeburg
  • Rochester
  • Butner
  • Charlotte
  • Raleigh
  • Beachwood
  • Cleveland
  • Lyndhurst
  • Norristown
  • Austin
  • Bellaire
  • DeSoto
  • Midvale
  • Milwaukee

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the effectiveness of lamotrigine for people with schizophrenia.

Who is behind this study?

The study sponsor is GlaxoSmithKline.

Did this study involve medication?

Yes. The study involved medication, including lamotrigine.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies